BR112016020366A2 - anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais - Google Patents
anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionaisInfo
- Publication number
- BR112016020366A2 BR112016020366A2 BR112016020366A BR112016020366A BR112016020366A2 BR 112016020366 A2 BR112016020366 A2 BR 112016020366A2 BR 112016020366 A BR112016020366 A BR 112016020366A BR 112016020366 A BR112016020366 A BR 112016020366A BR 112016020366 A2 BR112016020366 A2 BR 112016020366A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- eotaxin
- disorders
- ccr3
- recognize additional
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title abstract 2
- 108010012236 Chemokines Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 108010083647 Chemokine CCL24 Proteins 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
a invenção refere-se a anticorpos isolados poliespecíficos dirigidos a um epítopo exclusivo na quimiocina eotaxina 2, em que os anticorpos se ligam às quimiocinas de ligação a ccr3. a invenção também diz respeito à utilização desses anticorpos para atenuar a migração de várias células e para o tratamento de doenças fibróticas, distúrbios inflamatórias autoimunes, distúrbios relacionados a monócitos ou distúrbios atópicos alérgicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461947852P | 2014-03-04 | 2014-03-04 | |
US61/947,852 | 2014-03-04 | ||
PCT/IL2015/050234 WO2015132790A2 (en) | 2014-03-04 | 2015-03-04 | Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016020366A2 true BR112016020366A2 (pt) | 2018-06-05 |
BR112016020366B1 BR112016020366B1 (pt) | 2024-01-02 |
Family
ID=52815066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016020366-6A BR112016020366B1 (pt) | 2014-03-04 | 2015-03-04 | Anticorpo isolado que se liga a uma quimiocina de ligação a ccr3, molécula de ácido nucleico, vetor de expressão, célula hospedeira microbiana, e composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (2) | US10246508B2 (pt) |
EP (2) | EP4155317A1 (pt) |
JP (1) | JP6553075B2 (pt) |
CN (1) | CN106103479B (pt) |
BR (1) | BR112016020366B1 (pt) |
DK (1) | DK3114139T3 (pt) |
ES (1) | ES2926700T3 (pt) |
IL (1) | IL247219B (pt) |
PT (1) | PT3114139T (pt) |
RU (1) | RU2705255C2 (pt) |
WO (1) | WO2015132790A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017183028A1 (en) * | 2016-04-18 | 2017-10-26 | Chemomab Ltd. | Eotaxin-2 inhibitors in the treatment of fibromyalgia |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018139404A1 (ja) | 2017-01-24 | 2018-08-02 | 協和発酵キリン株式会社 | 放射線障害の治療又は予防剤並びに治療又は予防方法 |
GB201702500D0 (en) * | 2017-02-16 | 2017-04-05 | Univ Sheffield | Stable vamp reporter assay |
IL251024A0 (en) | 2017-03-08 | 2017-06-29 | Chemomab Ltd | Antibodies against eutaxin 2 for use in the treatment of liver diseases |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP3965710A4 (en) | 2019-03-08 | 2023-04-05 | Auris Health, Inc. | TILT MECHANISMS FOR MEDICAL SYSTEMS AND APPLICATIONS |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021214758A1 (en) | 2020-04-20 | 2021-10-28 | Chemomab Ltd. | Ccl24 inhibitors in the treatment of covid-19 |
WO2021214759A1 (en) | 2020-04-22 | 2021-10-28 | Chemomab Ltd. | Method of treatment using anti-ccl24 antibody |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1303736B1 (it) | 1998-11-11 | 2001-02-23 | San Raffaele Centro Fond | Peptidi derivati da rantes con attivita' anti-hiv. |
DK2046740T3 (da) * | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
AU2010209273A1 (en) | 2009-01-28 | 2011-09-01 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders |
IN2012DN01769A (pt) * | 2009-08-28 | 2015-06-05 | Vlst Corp | |
GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
-
2015
- 2015-03-04 EP EP22165244.9A patent/EP4155317A1/en active Pending
- 2015-03-04 US US15/122,241 patent/US10246508B2/en active Active
- 2015-03-04 JP JP2016555467A patent/JP6553075B2/ja active Active
- 2015-03-04 WO PCT/IL2015/050234 patent/WO2015132790A2/en active Application Filing
- 2015-03-04 PT PT157149634T patent/PT3114139T/pt unknown
- 2015-03-04 RU RU2016136639A patent/RU2705255C2/ru active
- 2015-03-04 CN CN201580011755.4A patent/CN106103479B/zh active Active
- 2015-03-04 EP EP15714963.4A patent/EP3114139B1/en active Active
- 2015-03-04 DK DK15714963.4T patent/DK3114139T3/da active
- 2015-03-04 BR BR112016020366-6A patent/BR112016020366B1/pt active IP Right Grant
- 2015-03-04 ES ES15714963T patent/ES2926700T3/es active Active
-
2016
- 2016-08-10 IL IL247219A patent/IL247219B/en unknown
-
2019
- 2019-02-07 US US16/270,231 patent/US10479830B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PT3114139T (pt) | 2022-09-13 |
DK3114139T3 (da) | 2022-09-12 |
RU2705255C2 (ru) | 2019-11-06 |
EP3114139A2 (en) | 2017-01-11 |
IL247219A0 (en) | 2016-09-29 |
WO2015132790A3 (en) | 2015-11-05 |
ES2926700T3 (es) | 2022-10-27 |
IL247219B (en) | 2021-09-30 |
US10479830B2 (en) | 2019-11-19 |
EP3114139B1 (en) | 2022-06-15 |
EP4155317A1 (en) | 2023-03-29 |
CN106103479B (zh) | 2019-12-24 |
BR112016020366B1 (pt) | 2024-01-02 |
CN106103479A (zh) | 2016-11-09 |
JP2017508461A (ja) | 2017-03-30 |
US10246508B2 (en) | 2019-04-02 |
RU2016136639A (ru) | 2018-04-05 |
US20160368979A1 (en) | 2016-12-22 |
WO2015132790A2 (en) | 2015-09-11 |
RU2016136639A3 (pt) | 2018-05-04 |
US20190153088A1 (en) | 2019-05-23 |
JP6553075B2 (ja) | 2019-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016020366A2 (pt) | anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais | |
BR112018012138A2 (pt) | moléculas de anticorpo para pd-1 e usos das mesmas | |
BR112018008891A8 (pt) | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos | |
CO2019014414A2 (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
BR112018010673A8 (pt) | moléculas de anticorpo para april e seus usos | |
BR112018072389A2 (pt) | anticorpos que reconhecem tau | |
BR112018013728A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias | |
EA201990594A1 (ru) | Анти-tim-3 антитела и их применение | |
BR112018072394A2 (pt) | anticorpos que reconhecem a tau | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
CO2019013935A2 (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
EA201691765A1 (ru) | Молекулы антител против lag-3 и их применения | |
BR112016024780A2 (pt) | composições e métodos relacionados com construtos de fc manipulados | |
BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
BR112019022906A2 (pt) | Anticorpos que reconhecem tau | |
BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
PE20180217A1 (es) | Anticuerpos anti-transtiretina | |
CO2017008482A2 (es) | Anticuerpos anti-transtiretina | |
BR112017009297A2 (pt) | anticorpos antifator de complemento c1q humanizados e usos dos mesmos | |
DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
CL2019000799A1 (es) | Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433) | |
BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
DE112017002304A5 (de) | Drehschwingungsdämpfer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/03/2015, OBSERVADAS AS CONDICOES LEGAIS |